Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Agenus (Details)

v3.22.2
Royalty and Commercial Payment Purchase Agreements - Agenus (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
item
Nov. 30, 2020
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Agreements              
Payments related to purchase of royalty rights and other commercial payment rights           $ 13,500  
Long-term royalty and commercial payment receivables     $ 66,575   $ 66,575   $ 69,075
Cash receipts for achievement of contractual milestones         0    
Revenue from contracts with customers     $ 525 $ 525 3,275 $ 544  
Impairment of long-term royalty receivable         0   0
Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus              
Agreements              
Amount of milestone achieved   $ 10,000          
Agenus | Royalty Purchase Agreement              
Agreements              
Payments related to purchase of royalty rights and other commercial payment rights $ 15,000            
Long-term royalty and commercial payment receivables $ 15,000            
Impairment of long-term royalty receivable         $ 0   $ 0
Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets              
Agreements              
Royalties entity has right to receive (as a percent) 33.00%            
Number of licensed products related to milestone and royalties | item 6            
Purchased percentage of milestones 10.00%            
Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product              
Agreements              
Royalties entity has right to receive (as a percent) 33.00%            
Purchased percentage of milestones 10.00%            
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500            
Amount of milestone achieved   1,000          
Cash receipts for achievement of contractual milestones   $ 1,000